French pharmaceutical company Sanofi is conducting negotiations with the European Union on the supply of 300 million doses of a potential vaccine against coronavirus, according to French television station BFMTV.
Sanofi is currently developing two vaccines against COVID-19.
According to company President Olivier Bajio similar to the affiliate transaction are prepared and with other countries, particularly the US and the UK. Bozio said that the company is capable of producing up to one billion doses per year.
State Secretary of the Ministry of economy and Finance of France Agnes Annie Renaker believes that through this arrangement the pharmaceutical group in the future to establish production of vaccines from COVID-19. According to her, the production of vaccine of this magnitude will result in a dramatic reinvestment in the pharmaceutical industry in Europe.
Clinical trials of the vaccine, which is being negotiated with the EU, to be held in September this year. It is expected that sales of the vaccine will be available in early 2021.
Special medications from COVID-19 does not exist now in this disease is only symptomatic treatment. The world health organization notedthat a number of medicines can contribute to improved well-being and relief of symptoms COVID-19, but there is no evidence that any drug to prevent or treat the disease.
The head of the European Agency of medicines Marco Kavaleri previously reported that a vaccine for the coronavirus in the best case will be ready next year. May 15, U.S. President Donald trump suggested that the coronavirus vaccine can be developed and tested by the end of 2020.
According to who, currently about 120 trials of a vaccine against coronavirus SARS-COV-2 / COVID-19 worldwide. While 17 of the vaccines now have on the people.